TY  - GEN
AU  - Ellis,Georgiana K
AU  - Barlow,William E
AU  - Gralow,Julie R
AU  - Hortobagyi,Gabriel N
AU  - Russell,Christy A
AU  - Royce,Melanie E
AU  - Perez,Edith A
AU  - Lew,Danika
AU  - Livingston,Robert B
TI  - Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012
SN  - 1527-7755
PY  - 2011///0509
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Biomarkers, Tumor
KW  - analysis
KW  - Breast Neoplasms
KW  - chemistry
KW  - Chemotherapy, Adjuvant
KW  - Chi-Square Distribution
KW  - Cyclophosphamide
KW  - administration & dosage
KW  - Disease-Free Survival
KW  - Doxorubicin
KW  - Drug Administration Schedule
KW  - Female
KW  - Granulocyte Colony-Stimulating Factor
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Logistic Models
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Neoplasm Staging
KW  - Odds Ratio
KW  - Paclitaxel
KW  - Proportional Hazards Models
KW  - Risk Assessment
KW  - Risk Factors
KW  - Time Factors
KW  - Treatment Outcome
KW  - United States
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1200/JCO.2009.27.6543
ER  -